KPTI · Program file
selinexor
Karyopharm Therapeutics Inc. (KPTI)
When did Karyopharm Therapeutics Inc. say selinexor results would come?
On , Karyopharm Therapeutics Inc. wrote in its SEC Form 10-Q: “We expect to report topline data from this event-driven trial in the second half of 2026.” (Source)
Days left in the window the company stated: 73 · company’s wording: “second half of 2026”
Last checked: .
Watch this program: confirm your email to start one daily alert digest.
Program file
- Name as filed
- selinexor
- Other names in filings
- EMN29 Trial · XPORT-MM-031
- Indication in the filing
- previously treated multiple myeloma
- Trials named in the same filing
- None listed
- Latest timing wording
- “We expect to report topline data from this event-driven trial in the second half of 2026.”
- Source
- 10-Q · filed · SEC accepted · accession 0001193125-26-347906 · SEC original
- Last checked
- Correction
- : The SEC acceptance time shown for selinexor (KPTI) on its program page was 2026-08-13T15:40:35Z, four hours later than the time in SEC's own header for the filing (10-Q, accession 0001193125-26-347906, filed 2026-08-13). It was shown from 2026-10-12, when the program file was published. Replaced with the header time, 2026-08-13T11:40:35Z. Checked on 2026-10-12 by reading the filing's SEC header; the other 14 program files matched. The review label is unchanged: the acceptance time is metadata, and the quoted wording and its source are unchanged. Earlier daily hashes and records are not changed; this correction is a new record. SEC header · Evidence · All corrections
Program KPTI-selinexor.